BT-483 Cells

The BT-483 cell line is derived from a human breast carcinoma. Specifically, these cells were established from a primary tumor of an adult female patient with breast cancer. BT-483 cells are characterized by their epithelial morphology and are adherent in culture, forming monolayers. This cell line is estrogen receptor-positive (ER+), making it particularly valuable for studying hormone-responsive breast cancers and the role of estrogen in breast cancer progression
Researchers use BT-483 cells to investigate various aspects of breast cancer biology, including hormone receptor signaling, gene expression profiles, and the cellular responses to different hormonal therapies. These cells are essential for testing the efficacy of anti-estrogen drugs, such as tamoxifen and aromatase inhibitors, which are commonly used in the treatment of ER+ breast cancers. Additionally, BT-483 cells provide a useful model for studying the mechanisms of drug resistance, tumor growth, and metastasis in hormone-responsive breast cancer.
The BT-483 cell line also serves as a tool for high-throughput screening of new therapeutic agents and for understanding the molecular basis of breast cancer heterogeneity. By comparing the responses of BT-483 cells to various treatments with other breast cancer cell lines, researchers can identify specific vulnerabilities and potential targets for therapy, ultimately contributing to the development of more effective and personalized treatments for breast cancer patients.